ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
Biogen Pharmachem Industries Limited has reported no unutilised funds from any prior capital raises, including public issues, rights issues, or preferential allotments, as of June 2026.
Biogen Pharmachem Industries submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The company confirmed compliance with all applicable SEBI regulations and secretarial standards.
Interface Financial Services Limited sold a 4.47% stake in Biogen Pharmachem Industries through the open market. This reduces their total equity holding to 4.84%.
Biogen Pharmachem Industries Limited confirmed it does not fall under the 'Large Corporate' category as per SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144. Consequently, the company is exempt from mandatory borrowing requirements and initial disclosure obligations for the financial year ended March 31, 2026.
Biogen Pharmachem Industries submitted its quarterly certificate under Regulation 74(5) of SEBI Regulations for the period ended March 31, 2026. The registrar confirmed that no physical share certificates were received for dematerialization during the quarter. This is a routine compliance filing with no material impact on business operations.